XD14

CAS No. 1370888-71-3

XD14 ( —— )

Catalog No. M22392 CAS No. 1370888-71-3

XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 88 In Stock
10MG 155 In Stock
25MG 312 In Stock
50MG 500 In Stock
100MG 705 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    XD14
  • Note
    Research use only, not for human use.
  • Brief Description
    XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
  • Description
    XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    BET bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1370888-71-3
  • Formula Weight
    421.51
  • Molecular Formula
    C20H27N3O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Daqiang P , Michel K , Lucas W , et al. Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7[J]. International Journal of Molecular ences, 2016, 17(10).
molnova catalog
related products
  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.

  • Menin-MLL inhibitor ...

    Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).

  • MS645

    MS645 is an inhibitor of bromodomain-containing protein 4 (BRD4) with a Ki of 18.4 nM for BRD4-BD1/BD2.